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Abstract: Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis 
is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis 
was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment 
outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of 
early RA is quite impossible, as the clinical criteria are insufﬁ  cient at the beginning stage of the disease. In 1998, Schellek-
en reported that a high percentage of RA patients had a speciﬁ  c antibody that could interact with a synthetic peptide which 
contained the amino acid citrulline. The high speciﬁ  city (98%) for RA of this new serological marker, anti-cyclic citrulli-
nated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence 
or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can 
be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement 
of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.
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Rheumatoid Factor and Anti-CCP Antibody in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disease of unknown origin, characterized by 
chronic joint inﬂ  ammation that may later develop into joint destruction, as well as functional limitation 
(1, 2). So far, the diagnosis has mainly depended on clinical manifestations. The laboratory test which 
may contribute to the diagnosis of RA is that for rheumatoid factor (3–6). However, the positive rate is 
approximately 70%. Since many rheumatic or immune diseases, including systemic lupus erythematosus 
(SLE), Sjogren’s syndrome (SS), primary cryoglobulinemia, and viral infection or tumor may develop 
positive RF, the speciﬁ  city of RF in RA is apparently lower (4,7–9). Therefore, it is necessary to search 
for other laboratory diagnostic markers with high sensitivity and high speciﬁ  city. 
Since 1960, many investigators used indirect immunoﬂ  urorescence and enzyme-linked immunosor-
bent tests to detect serologic antibodies in RA patients (10–15). These consisted of anti-perinuclear 
antibody (APF), anti-keratin antibody (AKA), anti-ﬁ  laggrin antibody (AF), anti-Sa, anti-RA 33, and 
others. Although the speciﬁ  city was higher (88%–99%) in some of those tests, the overall sensitivity 
(36%–59%) was lower and thereby limited their use as a routine laboratory test in RA.
Schelleken in 1988 reported that 76% of RA patients had a speciﬁ  c antibody which could interact 
with a synthetic peptide which contained the amino acid citrulline (16). The arginine of the original 
substrate from APF or AKA can be converted through a PAD (peptide arginine deaminase) enzyme to 
“citrulline”, which can be easily detected by anti-CCP antibody (anti-cyclic citrullinated antibody) 
(17–20). This modiﬁ  cation actually improves the speciﬁ  city up to 98%. Sensitivity recently increased 
to nearly 80% after we used the 2nd generation anti-CCP enzyme-linked immunosorbent test (ELISA) 
(21–23). 
In the past 5–6 years, many studies have focused on the value of the clinical application of anti-CCP 
antibody in rheumatoid arthritis and other rheumatic diseases (21–25). The high speciﬁ  city (98%) of 
anti-CCP in patients with RA can exclude other rheumatic or immune diseases in patients with positive 
anti-CCP (26–35). In addition, the anti-CCP antibody test may help us detect or recognize RA earlier 
(6, 36–43). In patients with RA, recent studies also demonstrated that high anti-CCP antibody had a 
poor radiological outcome (24, 25).Biomarker Insights 2007: 2 166
Chou et al
Anti-CCP in other rheumatic diseases
Many rheumatic or immune diseases can present 
the clinical symptoms of polyarticular, symmetrical 
arthritis and positive RF, which mimic RA or fulﬁ  ll 
the diagnosis of RA. These consist of SLE, SS, 
psoriatic arthritis (PSA) with polyarticular involve-
ment, HIV-related arthropathy, polymyalgia rheu-
matica (PMR), and even undifferentiated arthritis 
or palindromic rheumatism (PR) (26–37).
Anti-CCP antibody can be detected in a small 
percentage of patients with either rheumatic disease 
or immune disease (Table 1). One study measured 
the anti-CCP antibody in 126 patients with PSA. 
Only 7 out of 126 (5.6%) patients were positive 
for anti-CCP (27). However, the presence of anti-
CCP antibodies in PSA was signiﬁ  cantly associated 
with the HLA-DR1 shared epitope (p < 0.005), and 
even erosive disease (p < 0.05) or a number of 
swollen joints (p < 0.02) (27). Interestingly, Bock-
elmann found 11 of 62 (17.7%) psoriasis patients 
with PSA had a positive anti-CCP antibody, which 
was signiﬁ  cantly increased compared to the control 
group (4.1%, p < 0.01) (33). Gottenberg studied 
134 patients with primary SS, and 10 of the 134 
patients (7.5%) exhibited positive anti-CCP (30). 
Whether the real prevalence of anti-CCP in primary 
SS or the positive anti-CCP in primary SS patients 
renders them prone to developing RA requires 
long-term follow-up.
Palidromic rheumatism is a common rheumatic 
disease, characterized by recurrent self-limited 
arthritis. More than 50% of PR may evolve into RA 
years later. Salvador et al. demonstrated 18 of 32 
(56.3%) patients with pure PR had serologically 
positive anti-CCP antibody. The clinical syndrome 
can be considered as an abortive form of RA (44). 
Russell, in his early study, showed that 34% of cases 
with PR after years of follow-up (mean duration 6 
years) had progressed to RA (45). Recently, the same 
group demonstrated 29 of 61 PR patients (nearly 
50%) had progressed to RA. Among those 29 cases, 
83% had had anti-CCP antibodies in their baseline 
sera (36). They concluded that anti-CCP antibodies 
were better than RF in predicting outcome. 
RF can be detectable in cases with hepatitis C 
infection, with a prevalence ranging from 30% to 
60% (34, 46–48). In contrast to hepatitis C, the 
prevalence of hepatitis B virus (HBV) carriers in 
ethnic Chinese populations, including Taiwanese, 
was higher than in Caucasians. Therefore, the positive 
rheumatoid factor in Chinese with polyarthritis easily 
leads to the misdiagnosis of RA in HCV or HBV 
carriers. The lower prevalence of anti-CCP antibody 
in HCV-infected patients with arthralgia (5.7%) 
reported by Sene et al. (34) and 0% by Bombardieri 
(31) suggests anti-CCP antibodies are reliable 
markers to distinguish HCV-related arthropathy or 
Sjogren’s syndrome from RA (30, 31, 34, 46, 47).
PMR is a rheumatic disease that mainly affects 
elderly people. The persistent shoulder pain with 
morning stiffness and remarkable elevation of 
ESR or acute phase reactant makes it difﬁ  cult to 
distinguish PMR from elderly onset RA (EORA) 
with initial shoulder joint involvement (49). A 
recent study by Lopez-Hoyos showed that 75% 
of EORA patients had anti-CCP antibodies, 
whereas none of the PMR patients was positive 
for those antibodies (49). Therefore, the positive 
RF and anti-CCP antibodies can exclude the 
possibility of PMR early on.
The impact of rheumatoid factor 
and anti-CCP on extraarticular 
manifestations of RA.
The extraarticular manifestations of RA consist 
of rheumatoid nodules, interstitial lung disease 
or pleuritis, vasculitis, amyloidosis, scleritis, 
Table 1. The prevalence of anti-CCP in different rheumatic diseases.
Disease  Prevalence (%) of anti-CCP  Author
1. Psoriatic arthritis  17.7% (11/62)  Bockelmann R (Ref. 33)
   Control  4.1%  (9/98) 
2. Psoriatic arthritis  5.6% (7/126)  Korendowych E (Ref. 27)
   Control  0%  (0/97) 
3. Sjogren’s syndrome  7.5% (10/149)  Gottenberg JE (Ref. 30)
4. Sjogren’s syndrome  0% (0/7)  Sene D (Ref. 34)
5. HCV (+) with arthragia  5.7% (2/35)  Sene D (Ref. 34)
6. Polymyalgia rheumatica  0% (0/49)  Lopez-Hoyos M (Ref. 49)
7. Palidromic rheumatism (pure form)  56.3% (18/32)  Salvador G (Ref. 44)Biomarker Insights 2007: 2 167
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mononeuritis, and others. The positive correlation 
between RF and entraarticular manifestations was 
reported by De Rycke (50). However, Korkmaz 
did not ﬁ  nd a relationship between RF and extraar-
ticular manifestations (51).
Although anti-CCP antibodies are associated 
with the severity of RA and erosion, both Rycke 
and Korkmaz could not demonstrate a positive 
correlation between anti-CCP antibodies and 
extra-articular manifestations (50, 51). Many 
factors may affect the negative results, including 
patient sample sizes, disease duration and 
treatment (50, 51). Long-term follow-up of 
RA patients is required to understand the asso-
ciation between anti-CCP and extraarticular 
manifestations.
What is the relationship between the 
genetic and environmental factors of 
RA and anti-CCP antibody?
RA has long been recognized as an autoimmune 
disease which is genetically determined. HLA-
Class II alleles are the most important genetic 
marker that increases the risk of developing RA 
(52). The shared epitope (SE) of HLA-Class II 
alleles indicates they share the conserved amino 
acid sequence, and constitute a part of the antigen-
binding site (53). These SE alleles are located in 
the third hypervariable region of the HLA-DRB1 
molecules (QKRAA, QRRAA or RRRAA). Many 
SE alleles have been studied, including DRB1, 
0101, 0102, 0104, 0401, 0404, 0405, and 0408, 
and among them, 0101, 0401 and 0404 were 
highly associated with RA in Caucasians (54–57). 
To explore the association among SE, anti-CCP 
and RA, many investigators found that HLA-
DRB1 alleles encoding the SE were only associ-
ated with RA in the presence of anti-CCP 
antibodies, and were not associated with anti-CCP 
negative RA (58–62).
Recently, the North American RA Consortium 
family cohort and the Study of New Onset RA 
cohort further investigated 1723 Caucasian RA 
patients and reconﬁ  rmed that HLA-DRB1 SE was 
strongly associated with anti-CCP (63). In this 
study, several interesting ﬁ  ndings were observed. 
Unlike anti-CCP antibody, SE was not signiﬁ  cantly 
associated with the presence of RF (63). Addition-
ally, HLA-DR3 alleles were negatively associated 
with positive anti-CCP and easily found in anti-
CCP negative individuals. In cases with DR3 
positive RA, the anti-CCP antibody level was lower 
compared to DR3 negative RA. Verpoort conﬁ  rmed 
the ﬁ  nding that HLA-DR3 was associated with 
anti-CCP negative arthritis, but not with anti-CCP 
positive arthritis (64). 
The interaction between SE alleles and citrul-
linated peptide antigen may be the pathogenetic 
mechanism that increases the anti-CCP antibody 
production in RA (17). However, citrullinated 
peptide antigen was found not only in RA 
synovium, but also in other diseases (65). This was 
proposed as an abnormal humoral response to these 
citrullinated proteins in RA patients, and requires 
further identiﬁ  cation. 
For juvenile RA, HLA-DR4 positive patients 
with polyarticular onset were more likely to have 
anti-CCP antibodies than those without HLA-DR4 
(OR 5.20, CI 1.30–20.9) (66). Interestingly, the 
presence of anti-CCP antibodies in 7 patients with 
psoriatic arthritis (PSA) was also signiﬁ  cantly 
associated with HLA-DRB1 SE (0101, 0401) 
(p < 0.005) and erosive disease (27). Among these 
7 PSA patients, 4 showed a polyarticular pattern. 
For either JRA or PSA, the frequency of anti-CCP 
antibody in these patients was rather low (5–10%), 
and the presence of anti-CCP associated with HLA-
Class II SE was mainly noticed in polyarticular-
type cases. Up to now, the relationship between 
the anti-CCP antibody and SE with a polyarticular 
subtype in either JRA or PSA remains unknown. 
Follow-up is strongly indicated, particularly for 
the JRA cases that eventually develop adult RA or 
other diseases.
The environmental factors in RA are multiple. 
Among them, smoking is a risk factors for RA, and 
this is evidenced by the fact that smokers have 
increased levels of RF (67–69) and are prone to 
develop RA (70–72). By combining anti-CCP and 
SE, Linn-Risker et al. concluded that smoking 
increases the risk for anti-CCP antibodies only in 
shared epitope-positive patients with RA (58). 
Swedish investigators demonstrated that both SE 
and smoking resulted in an increased risk, specif-
ically for RF positive RA (73).
However, it is quite difficult to identify the 
possible pathogenic pathways through which 
smoking confers a high risk of developing RA 
in SE-positive individuals. Whether smoking 
can increase the proinflammatory cytokines 
or destroy the tolerance to citrinullated 
proteins remains unknown and needs further 
investigation (58). Biomarker Insights 2007: 2 168
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Prognositive factors of anti-CCP 
antibody in rheumatoid arthritis
Many recent studies have shown that anti-CCP 
antibody can predict the severity of either the 
clinical or radiological outcome in RA patients 
(24, 25, 74–80). Forslind showed that anti-CCP 
positive early RA patients had a higher Larsen 
score at baseline compared to anti-CCP negative 
RA patients, and had significant radiological 
damage after years of follow-up (25). Kastbom 
reconfirmed that anti-CCP antibody positivity 
at diagnosis predicted higher disease activity 
over the following 3 years of recent-onset RA 
(24). The presence of anti-CCP antibody or 
anti-perinuclear factor in RA patients, instead 
of RF, presented an increased total sharp score 
after 5 years of follow-up (74). When comparing 
erosive and non-erosive RA patients, the levels 
of anti-CCP antibodies and ESR were 
significantly higher in erosive RA patients (75). 
Aotsuka et al. measured anti-CCP antibody in 
RA patients during the period 1982–2004 and 
found that anti-CCP levels tended to fluctuate 
in parallel with the ESR or CRP level (78).
We recently enrolled 155 ethnic Chinese RA 
patients and divided them into anti-CCP posi-
tive (110) and anti-CCP negative (45) patients. 
There were no significant differences in the 
demographic data (age, gender, disease duration 
and treatment, etc.) between the 2 groups. 
Rheumatoid factor was significantly higher in 
the anti-CCP positive group than in the anti-
CCP negative group (77.3% vs. 37.8%, 
p < 0.0001). All the clinical parameters (number 
of tender joints and swollen joints) and labora-
tory data (ESR, CRP) were significantly greater 
in anti-CCP positive than in anti-CCP negative 
patients (p < 0.05, < 0.01). The DAS score in 
the anti-CCP positive group was 4.30 (2.03–
7.52) and in the anti-CCP negative group was 
3.69 (2.03–6.54), which revealed a significant 
difference between the 2 groups (p = 0.007) 
(unpublished data). Our results differed from 
those of the study by van der Helm et al. who 
showed no significant difference in disease 
activity and CRP between RA patients with and 
without anti-CCP antibodies (77). We have to 
continue following up our RA patients in order 
to understand whether the presence of anti-CCP 
in Chinese RA patients can determine the poor 
clinical and radiological outcome, as in 
Caucasian patients.
Can serum anti-CCP antibody level 
be used as a useful adjunct in 
assessing drug efﬁ  cacy?
The 2 most common laboratory tests that we use 
to evaluate RA disease activity and treatment efﬁ  -
cacy are ESR and CRP. In certain RA patients, the 
clinical manifestations may not be correlated well 
with ESR and CRP. Searching for other disease 
activity markers in order to assess clinical improve-
ment after a speciﬁ  c drug therapy is important. 
After biological therapy, a signiﬁ  cant improvement 
in clinical features, including pain, stiffness and 
swelling has been noticed. Apart from that, both 
ESR and CRP can be reduced signiﬁ  cantly within 
3 months after treatment (81, 82). Several groups 
have recently studied the RF and anti-CCP levels 
before and after TNF-alpha inhibitors (83–88).
The positive rate for anti-CCP antibody before 
inﬂ  iximab or etanercept treatment ranged from 
83% to 90%, and for RF, from 78% to 95%. The 
higher frequency of anti-CCP or RF was mainly 
due to the severe RA patients who were enrolled 
in the study (81, 83–86, 89). Alessandri treated 43 
RA patients with inﬂ  iximab and found the serum 
titer of anti-CCP and RF decreased signiﬁ  cantly 
after 6 months of treatment (83). In contrast, there 
was no signiﬁ  cant change in ESR and CRP before 
and after inﬂ  iximab. Two other studies demon-
strated that RF, but not anti-CCP, was signiﬁ  cantly 
reduced after infliximab treatment. (84, 89). 
Bobbon-Pallaricini investigated the effect of long-
term inﬂ  iximab treatment (up to 78 weeks) on 
anti-CCP, RF, anti-DNA, etc. The results showed 
a signiﬁ  cant reduction of RF from 128 IU/ul (base-
line) to 53 IU/ul (78 weeks). However, anti-CCP 
antibody signiﬁ  cantly decreased at 30 weeks, but 
returned to baseline thereafter (85). A more inter-
esting ﬁ  nding was reported by Braun-Moscovici, 
who demonstrated a positive correlation between 
lower baseline levels of anti-CCP and clinical 
response to infliximab (86). Our recent study 
demonstrated ﬁ  ndings similar to those of Alles-
sandri, except that the biological agent we used 
was etanercept (81). A signiﬁ  cant reduction of 
serum levels of anti-CCP and RF was found in 
patients who received etanercept combined with 
DMARDs, compared to patients with DMARDs 
alone (p = 0.007 and p = 0.006 respectively). In 
addition, a positive correlation between anti-CCP 
antibody titer and variation in disease activity, 
swollen and tender joint counts, RF and CRP was 
observed without biological therapy. DMARDs Biomarker Insights 2007: 2 169
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also reduced the anti-CCP or RF level by 25%, but 
only shorter disease duration (≤12 months) was 
signiﬁ  cantly correlated with a decline in the levels 
of anti-CCP antibody (90).
In conclusion, short-term biological therapy (<6 
weeks) can effectively suppress the serum anti-
CCP level in RA patients. The long-term (>1 year) 
efﬁ  cacy of TNF-alpha inhibitor for the serum anti-
CCP antibody level is not conclusively known now, 
and requires further study.
Conclusion
Anti-CCP has become a “key” serologic marker in 
RA. It can be used (1) as a test for early diagnosis 
of RA; (2) for the differential diagnosis between 
RA and other rheumatic or immune diseases; (3) 
for prediction of prognosis; and (4) for evaluation 
of treatment outcome.
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